PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids
Update: 2024-12-30
Description
In this podcast recorded in early December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2025 issue of DTB. They provide an overview of the editorial that questions whether it is time for the medicine Patient Information Leaflet (PIL) to include information on the impact of a medicine on clinical outcomes - https://dtb.bmj.com/content/63/1/2. They talk about a recent announcement from the Irish College of GPs that it is phasing out sponsorship from pharmaceutical companies as evidence suggests that ‘engagement between pharmaceutical companies and prescribers is associated with inappropriately increased prescribing rates, lower prescribing quality and increased prescription costs’ - https://dtb.bmj.com/content/63/1/3. The main article provides an overview of Ryeqo (relugolix, estradiol and norethisterone acetate) for the treatment of moderate to severe symptoms of uterine fibroids - https://dtb.bmj.com/content/63/1/6. The podcast ends with a farewell to James, who is stepping down as Editor-in-Chief after more than 12 years. James reflects on his time as a doctor, GP and Editor of DTB.
Other links:
Is ASCOT all it's cracked up to be? https://www.bmj.com/content/331/7523/1023.1
Don't lose your head over ASCOT https://www.bmj.com/content/331/7523/1022.1
Other links:
Is ASCOT all it's cracked up to be? https://www.bmj.com/content/331/7523/1023.1
Don't lose your head over ASCOT https://www.bmj.com/content/331/7523/1022.1
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
